Glaukos to Present Multiple Scientific Abstracts at ASCRS Annual Meeting

Glaukos to showcase new corneal cross-linking treatment at leading ophthalmology conference.

Apr. 6, 2026 at 3:36pm

Got story updates? Submit your updates here. ›

A highly detailed, translucent X-ray photograph revealing the complex internal structure of the human cornea, with delicate lines and shapes in shades of blue and violet against a dark background, conceptually illustrating the advanced technology behind Glaukos' new corneal cross-linking treatment.Glaukos' new Epioxa treatment aims to strengthen the cornea through an innovative, non-invasive cross-linking procedure.Aliso Viejo Today

Glaukos Corporation, a leading ophthalmic pharmaceutical and medical technology company, announced that it will present multiple scientific abstracts at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The company's presentations will focus on its new FDA-approved corneal cross-linking treatment, Epioxa, which is the first and only epithelium-on, oxygen-enriched therapy of its kind.

Why it matters

Glaukos is a major player in the ophthalmology industry, and its new Epioxa treatment represents a significant advancement in corneal cross-linking technology. The ASCRS Annual Meeting is a prestigious event where leading eye care professionals gather to share the latest research and innovations, making Glaukos' presence there an important milestone for the company and the broader corneal health community.

The details

Epioxa is Glaukos' new FDA-approved corneal cross-linking treatment that uses an oxygen-enriched formula to strengthen and stabilize the cornea without requiring the removal of the epithelium, the outermost layer of the cornea. This represents a significant improvement over traditional cross-linking procedures, which can be more invasive and require a longer recovery period for patients.

  • The 2026 ASCRS Annual Meeting will take place from April 17-21, 2026.

The players

Glaukos Corporation

An ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Epioxa

Glaukos' new FDA-approved corneal cross-linking treatment that uses an oxygen-enriched formula to strengthen and stabilize the cornea without requiring the removal of the epithelium.

Got photos? Submit your photos here. ›

What’s next

Glaukos will showcase Epioxa and present its latest research findings at the 2026 ASCRS Annual Meeting in April.

The takeaway

Glaukos' presentation of Epioxa at the prestigious ASCRS conference highlights the company's commitment to advancing corneal health treatments and bringing innovative solutions to eye care professionals and patients.